<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Estimated risks for cancer with &lt;em&gt;BRCA1&lt;/em&gt; and &lt;em&gt;BRCA2&lt;/em&gt; pathogenic variants</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Estimated risks for cancer with <em>BRCA1</em> and <em>BRCA2</em> pathogenic variants</h1>
<div class="graphic"><div class="figure"><div class="ttl">Estimated risks for cancer with <em>BRCA1</em> and <em>BRCA2</em> pathogenic variants</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="20%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr> <td class="subtitle1">Cancer type</td> <td class="subtitle1">Lifetime risk to age 70 in carriers*</td> <td class="subtitle1">Lifetime risk to age 70 in general population<sup>¶</sup></td> <td class="subtitle1">Comments</td> </tr> <tr> <td>Breast (female)</td> <td> <p><em>BRCA1</em>: 57 to 72%</p> <em>BRCA2</em>: 45 to 69%</td> <td>9%</td> <td> <p>In most studies, lifetime risk in <em>BRCA1</em> carriers is higher than that observed in <em>BRCA2</em> carriers.</p> The incidence of breast cancer diagnosed younger than 50 years of age is higher in <em>BRCA1</em> carriers compared with <em>BRCA2</em> carriers, but both groups have an increased risk of premenopausal breast cancer.</td> </tr> <tr> <td>Contralateral (opposite) breast (female)</td> <td>Up to 63% at 25 years postdiagnosis but highly dependent on age at diagnosis of first breast cancer</td> <td>0.4% annual risk and 10% at 25 years postdiagnosis<sup>[1]</sup></td> <td> <p>Risk is affected by other factors such as tamoxifen use and oophorectomy.</p> Mutation carriers who have had lumpectomy have increased ipsilateral risks over long follow-up periods.</td> </tr> <tr> <td>Ovarian</td> <td> <p><em>BRCA1</em>: 39 to 59%</p> <em>BRCA2</em>: 11 to 20%</td> <td>1%</td> <td> <p>The incidence of ovarian cancer diagnosed younger than 50 years of age is higher in <em>BRCA1</em> carriers and overall rare in all carriers younger than 40 years old.</p> Risk of fallopian tube cancer is also substantially elevated.</td> </tr> <tr> <td>Prostate</td> <td> <p><em>BRCA1</em>: Approximately 15 to 20%</p> <em>BRCA2</em>: Approximately 13 to 30%</td> <td> <p>6% White Americans</p> 10% Black Americans</td> <td>Risk appears to be higher in <em>BRCA2</em> carriers and in males younger than 65 years old.</td> </tr> <tr> <td>Breast (male)</td> <td> <p><em>BRCA1</em>: 0.2 to 1%</p> <em>BRCA2</em>: 2 to 7%</td> <td>0.1%</td> <td>Risk before age 50 is very low.</td> </tr> <tr> <td>Pancreatic</td> <td> <p><em>BRCA1</em>: 1 to 3%</p> <em>BRCA2</em>: 2 to 5%</td> <td>0.6%</td> <td> </td> </tr> <tr> <td>Colon</td> <td>Not well defined</td> <td>2%</td> <td>Studies have not been consistent about whether risk is elevated. If elevated, risk is likely to be small.</td> </tr> <tr> <td>Melanoma</td> <td>Not well defined</td> <td> <p>Approximately 2% White Americans</p> 0.1% Black Americans</td> <td>Increased risk for ocular melanoma in <em>BRCA2</em> carriers.</td> </tr> <tr> <td>Other sites</td> <td>Not well defined</td> <td>Varied</td> <td>These sites may include cancer of the stomach, gall bladder, and biliary tree in <em>BRCA2</em> carriers, as well as uterine serous carcinoma in <em>BRCA1</em> and <em>BRCA2</em> carriers.</td> </tr> </tbody></table></div><div class="graphic_lgnd">These risks are estimates based upon review of the literature that focuses on individuals identified based on a positive family history. Risk may differ (ie, may be lower) in individuals with a negative family history, although data are extremely limited. Specific studies have reported risks that are lower or higher than the ranges or estimates quoted; however, the estimates reported here are representative of findings from high-quality studies in <em>BRCA1</em> and <em>BRCA2</em> families. Risks will also vary based on an individual's current age and other risk factors. (Refer to UpToDate topic on cancer risks and management of <em>BRCA1/2</em> carriers without cancer.)</div><div class="graphic_footnotes"><p><em>BRCA</em>: breast cancer susceptibility genes; SEER: Surveillance, Epidemiology, and End Results.</p>
<p>* Risk to individuals over age 70 is higher, but data are generally unavailable.</p>
¶ Lifetime risk at birth for all races unless otherwise specified.</div><div class="graphic_reference"><p>Data from: DevCan Version 6.7.9, April 2021, National Cancer Institute. Available at <a href="https://surveillance.cancer.gov/devcan/" target="_blank">https://surveillance.cancer.gov/devcan/</a> (Accessed on April 29, 2022).</p>
Reference:
<ol>
<li>Giannakeas V, Lim DW, Narod SA, et al. The risk of contralateral breast cancer: a SEER-based analysis. Br J Cancer 2021; 125:601.</li>
</ol></div><div id="graphicVersion">Graphic 99937 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
